Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Clin Invest ; 133(14)2023 07 17.
Artículo en Inglés | MEDLINE | ID: mdl-37200096

RESUMEN

Hypertrophic cardiomyopathy (HCM) is the most prominent cause of sudden cardiac death in young people. Due to heterogeneity in clinical manifestations, conventional HCM drugs have limitations for mitochondrial hypertrophic cardiomyopathy. Discovering more effective compounds would be of substantial benefit for further elucidating the pathogenic mechanisms of HCM and treating patients with this condition. We previously reported the MT-RNR2 variant associated with HCM that results in mitochondrial dysfunction. Here, we screened a mitochondria-associated compound library by quantifying the mitochondrial membrane potential of HCM cybrids and the survival rate of HCM-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in galactose media. 1-Deoxynojirimycin (DNJ) was identified to rescue mitochondrial function by targeting optic atrophy protein 1 (OPA1) to promote its oligomerization, leading to reconstruction of the mitochondrial cristae. DNJ treatment further recovered the physiological properties of HCM iPSC-CMs by improving Ca2+ homeostasis and electrophysiological properties. An angiotensin II-induced cardiac hypertrophy mouse model further verified the efficacy of DNJ in promoting cardiac mitochondrial function and alleviating cardiac hypertrophy in vivo. These results demonstrated that DNJ could be a potential mitochondrial rescue agent for mitochondrial hypertrophic cardiomyopathy. Our findings will help elucidate the mechanism of HCM and provide a potential therapeutic strategy.


Asunto(s)
1-Desoxinojirimicina , Cardiomiopatía Hipertrófica , Animales , Ratones , 1-Desoxinojirimicina/farmacología , 1-Desoxinojirimicina/metabolismo , Cardiomiopatía Hipertrófica/tratamiento farmacológico , Cardiomiopatía Hipertrófica/genética , Cardiomiopatía Hipertrófica/metabolismo , Mitocondrias/metabolismo , Miocitos Cardíacos/metabolismo , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/genética , Cardiomegalia/metabolismo
2.
Adv Mater ; 34(3): e2106502, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34750894

RESUMEN

Monolayer transition metal dichalcogenides (TMDs) have emerged as widely accepted 2D gain materials in the field of light sources owing to their direct bandgap and high photoluminescence quantum yield. However, the monolayer medium suffers from weak emission because only a single layer of molecules can absorb the pump energy. Moreover, the material degradation when transferring these fragile materials hinders their cooperation with the optical cavity further. In this study, for the first time, a high-quality monolithic structure is developed by directly growing single-domain tungsten diselenide (WSe2 ) bilayers on single silica microsphere (MS) cavities. Such a completely wrapped structure guides the indirect-to-direct bandgap transition of WSe2 bilayers, leading to a significantly improved photoluminescence intensity by about 60-fold. Moreover, the high-quality monolithic structure enhances the confinement factor of the cavity by more than 20-fold. Based on the above advantages, a bilayer WSe2 /MS microlaser is realized with an ultralow threshold of 0.72 W cm-2 , nearly an order of magnitude lower than the existing records. The results demonstrate the possibility of using multilayer TMD materials as 2D gain media and provide insights into a new ultracompact monolithic platform of TMD material/cavity for lasing devices.

3.
J Zhejiang Univ Sci B ; 20(5): 449-456, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-31090270

RESUMEN

Mitochondrion is a semi-autonomous organelle, important for cell energy metabolism, apoptosis, the production of reactive oxygen species (ROS), and Ca2+ homeostasis. Mitochondrial DNA (mtDNA) mutation is one of the primary factors in mitochondrial disorders. Though much progress has been made, there remain many difficulties in constructing cell models for mitochondrial diseases. This seriously restricts studies related to targeted drug discovery and the mechanism and therapy for such diseases. Here we summarize the characteristics of patient-specific immortalized lymphoblastoid cells, fibroblastoid cells, cytoplasmic hybrid (cybrid) cell lines, and induced pluripotent stem cells (iPSCs)-derived differentiation cells in the study of mitochondrial disorders, as well as offering discussion of roles and advances of these cell models, particularly in the screening of drugs.


Asunto(s)
ADN Mitocondrial/metabolismo , Descubrimiento de Drogas , Enfermedades Mitocondriales/metabolismo , Animales , Apoptosis , Calcio/metabolismo , Diferenciación Celular , Línea Celular , Citoplasma/metabolismo , Metabolismo Energético , Fibroblastos/citología , Homeostasis , Humanos , Células Madre Pluripotentes Inducidas/citología , Linfocitos/citología , Mitocondrias/metabolismo , Mutación , Fenotipo , Especies Reactivas de Oxígeno/metabolismo
4.
Mitochondrion ; 46: 313-320, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30196098

RESUMEN

Hypertrophic cardiomyopathy (HCM), affecting approximately 1 in 500 in the general population, is the most prominent cause of sudden heart disease-related mortality in the young. Mitochondrial DNA (mtDNA) mutations are among the primary causes of HCM. We previously identified a novel m.2336T>C homoplasmic mutation in the mitochondrial 16S rRNA gene (MT-RNR2) in a Chinese maternally inherited HCM family. However, the molecular mechanisms by which m.2336T>C mutation contributes to HCM remain elusive. Here we generated transferring mitochondria cell lines (cybrids) with a constant nuclear background by transferring mitochondria from immortalized lymphoblastoid cell lines carrying the HCM-associated m.2336T>C mutation into human mtDNA-less (ρ°) cells. Functional assays showed a decreased stability for 16S rRNA and the steady-state levels of its binding proteins in the mutant cybrids. This mutation impaired the mitochondrial translation capacity and resulted in many mitochondrial dysfunctions, including elevation of ROS generation, reduction of ATP production and impairment of mitochondrial membrane potential. Moreover, the mutant cybrids had poor physiological status and decreased survival ability. These results confirm that the m.2336T>C mutation leads to mitochondrial dysfunction and strongly suggest that this mutation may play a role in the pathogenesis of HCM.


Asunto(s)
Cardiomiopatía Hipertrófica/genética , ADN Mitocondrial/genética , Mitocondrias/patología , Mutación Puntual , ARN Ribosómico 16S/genética , Supervivencia Celular , Metabolismo Energético , Salud de la Familia , Humanos , Mitocondrias/genética , Biosíntesis de Proteínas , Estabilidad del ARN , ARN Ribosómico 16S/metabolismo , Proteínas de Unión al ARN/metabolismo , Especies Reactivas de Oxígeno/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...